The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for stakeholders considering the pharmaceutical sector. While its groundbreaking success and impact of vast in earnings , the intellectual property end has opened the floodgates for competing medications, substantially reducing earnings potential . This shift